Microalbuminuria in treated hypertensives: Only a mirror image of cardiovascular risk?

Scandinavian Journal of Primary Health Care

Volumn 24, Issue 3, 2006, Pages 145-153

  Kvenild, Kurt ^a,d   Romundstad, Solfrid ^a,b   Midthjell, Kristian ^a   Krüger, Øystein ^c   Hallan, Hans ^b   Holmen, Jostein ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Levanger Hospital   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d HUNT Research Centre   (Norway)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Family practice; Microalbuminuria; Treated hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACADEMIC ACHIEVEMENT; ADULT; AGE DISTRIBUTION; AGED; AGING; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CREATININE BLOOD LEVEL; DISEASE MARKER; FEMALE; GENERAL PRACTICE; HEALTH SURVEY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NORWAY; PULSE PRESSURE; SELF REPORT; SEX RATIO; SMOKING; STATISTICAL ANALYSIS; STROKE; URINALYSIS; WAIST HIP RATIO;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33747684173     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.1080/02813430600673604     Document Type: Article

References (32)

1. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: A systematic overview of the literature: Arch Intern Med 1997;157:1413-8.
2. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia 1999;42:263-85.
3. Bog-Hansen E, Merlo J, Gullberg B, Melander A, Rastam L, Lindblad U. Survival in patients with hypertension treated in primary care: A population-based follow-up study in Skaraborg Hypertension and Diabetes Prosject. Scand J Prim Health Care 2004;22:222-7.
4. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7.
5. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249:519-26.
6. Romundstad S, Holmen J, Hallan H, Kvenild K, Kruger O, Midthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population: The Nord-Trondelag Health Study (HUNT, 1995-97), Norway. J Intern Med 2002;252:164-72.
7. Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H. Clinical relevance of microalbuminuria screening in self-reported non-diabetic/non- hypertensive persons identified in a large health screening - The Nord-Trondelag Health Study (HUNT), Norway. Clin Nephrol 2003;59:241-51.
8. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325-33.
9. Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Berruti V, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998;11:430-8.
10. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: A populationbased study of 1254 hypertensive individuals. J Hum Hypertens 1997;11:727-32.
11. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997;30:1135-43.
12. Viazzi F, Leoncini G, Parodi D, Ravera M, Ratto E, Vettoretti S, et al. Pulse pressure and subclinical cardiovascular damage in primary hypertension. Nephrol Dial Transplant 2002;17:1779-85.
13. Martinez MA, Moreno A, Aguirre dC, Cabrera R, Rocha R, Torre A, et al. Frequency and determinants of microalbuminuria in mild hypertension: A primary-care-based study. J Hypertens 2001;19:319-26.
14. Pedrinelli R, Dell'Omo G, Penno G, Bandinelli S, Bertini A, Di B V, et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35: 48-54.
15. Cuspidi C, Lonati L, Sampieri L, Michev I, Macca G, Rocanova JI, et al. Prevalence of target organ damage in treated hypertensive patients: Different impact of clinic and ambulatory blood pressure control. J Hypertens 2000;18:803-9.
16. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002;39:794-8.
17. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
18. Holmen J, Midthjell K, Krüger Ø, Langhammer A, Bratberg G, Vatten L, et al. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003;13:19-32.
19. Hallan H, Romundstad S, Kvenild K, Holmen J. Microalbuminuria in diabetic and hypertensive patients and the general population. Scand J Urol Nephrol 2003;37:151-8.
20. Giampietro O, Penno G, Clerico A, Cruschelli L, Lucchetti A, Nannipieri M, et al. Which method for quantifying "microalbuminuria" in diabetics? Comparison of several immunological methods (immunoturbidimetric assay, immunonephelometric assay, radioimmunoassay and two semiquantitative tests) for measurement of albumin in urine. Acta Diabetol 1992;28:239-45.
21. Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum and early morning urine. Clin Lab 2000;46:53-5.
22. Jensen JS, Clausen P, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997;12(Suppl 2):6-9.
23. Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003;21:1199-205.
24. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
25. Verhave JC, Hillege HL, Burgerhof JG, Navis G, De Zeeuw D, De Jong PE. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women J Am Soc Nephrol 2003;14:1330-5.
26. Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001;38:1372-5.
27. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999;22:307-13.
28. Pontremoli R, Leoncini G, Viazzi F, Parodi D, Vaccaro V, Falqui V, et al. Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2005;16(Suppl 1):S39-S41.
29. Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, et al. Optimizing global risk evaluation in primary hypertension: The role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 2004;22:907-13.
30. Getz L, Kirkengen AL, Hetlevik I, Romundstad S, Sigurdsson JA. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice: A descriptive epidemiological study. Scand J Prim Health Care 2004;22:202-8.
31. Hetlevik I, Holmen J, Kruger O, Kristensen P, Iversen H. Implementing clinical guidelines in the treatment of hypertension in general practice. Blood Press 1998;7:270-6.
32. Getz L, Sigurdsson JA, Hetlevik I. Is opportunistic disease prevention in the consultation ethically justifiable? BMJ 2003;327:498-500.